Kirsten Johnson

Dr. Kirsten Johnson

The Fragile X Society, Great Dunmow, Essex, UK
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 May 2020 in Frontiers in Pediatrics
Verified
Journal Article
Open access
PDF file
Kirsten JohnsonKirsten Johnson
Kirsten Johnson
JHJonathan Herring
Jonathan Herring
JRJörg Richstein
Jörg Richstein
The European Fragile X Network (EFXN) proposes that Fragile X Premutation Associated Conditions (FXPAC) be adopted as a universal term covering any condition linked to the Fragile X premutation. To date, there has not been an umbrella term assigned to issues associated with the FMR1 premutation, though several defined conditions which affect some premutation carriers, namely Fragile X-associated Primary Ovarian Insufficiency (FXPOI) and Fragile X-associated Tremor/Ataxia Syndrome (FXTAS), are now commonly accepted. An overarching term covering all FX premutation conditions will help doctors in determining how the premutation might be affecting their patient; and encourage researchers to explore the interrelationships of the various conditions affecting premutation carriers. Further, there are ongoing discoveries about physical and psychological issues faced by premutation carriers, and a new term helps encompass all of these burgeoning developments.

19 March 2022 in Cells
Verified
Journal Article
Open access
PDF file
JHJonathan Herring
Jonathan Herring
Kirsten JohnsonKirsten Johnson
Kirsten Johnson
JRJörg Richstein
Jörg Richstein
The European Fragile X Network met in Wroclaw, Poland, November 2021, and agreed to work towards the eradication of the word “retardation” in regard to the naming of the fragile X gene (FRAXA) and protein (FMRP). There are further genes which have “retardation” or abbreviations for “retardation” in their names or full designations, including FMR1, FMR2, FXR1, FXR2, NUFIP1, AFF1, CYFIP1, etc. “Retardation” was commonly used as a term in years past, but now any reference, even in an abbreviation, is offensive. This article discusses the stigmatisation associated with “retardation”, which leads to discrimination; the inaccuracy of using “retardation” in these designations; and the breadth of fragile X syndrome being beyond that of neurodiversity. A more inclusive terminology is called for, one which ceases to use any reference to “retardation”. Precedents for offensive gene names being altered is set out. The proposal is to approach the HGNC (HUGO [Human Genome Organisation] Gene Nomenclature Committee) for new terminology to be enacted. Ideas from other researchers in the field are welcomed.

21 February 2024 in Journal of Applied Research in Intellectual Disabilities
Verified
Journal Article
Open access
Kirsten JohnsonKirsten Johnson
Kirsten Johnson
ASAndrew C. Stanfield
Andrew C. Stanfield
GSGaia Scerif
Gaia Scerif
AMAndrew McKechanie
Andrew McKechanie
ACAngus Clarke
Angus Clarke
HCHayley Crawford
Hayley Crawford
Background: The Fragile X community has expressed a desire for centralised, national guidelines in the form of integrated guidance for Fragile X Syndrome (FXS).Methods: This article draws on existing literature reviews, primary research and clinical trials on FXS, a Fragile X Society conference workshop and first‐hand experience of clinicians who have worked with those living with FXS over many years.Results: The article scopes proposed integrated guidance over the life course, including appendices of symptoms, comorbidities and referral options for FXS and Fragile X Premutation Associated Conditions.Conclusion: Integrated guidance would provide an authoritative source for doctors, health professionals, therapists, care workers, social workers, educators, employers, families and those living with FXS, so that a holistic, person‐centred approach can be taken across the United Kingdom to garner the best outcomes for those with FXS.

1 January 2024 in Neurodiversity
Verified
Journal Article
Open access
JHJonathan Herring
Jonathan Herring
Kirsten JohnsonKirsten Johnson
Kirsten Johnson
GSGaia Scerif
Gaia Scerif
EWEmilie Weight
Emilie Weight
JRJörg Richstein
Jörg Richstein
KEKatherine Ellis
Katherine Ellis
The purpose of this article is to provide a positive framework for a doctor, geneticist, genetic counsellor or other professional to deliver a fragile X syndrome diagnosis and to offer support thereafter. Our aim is not to glamourise the condition nor downplay its impacts but rather to suggest that a more accurate and holistic definition of fragile X syndrome would cover all the aspects of the condition, including its variability and positive aspects. Fragile X syndrome is commonly described in terms of the ‘problems’ associated with it and stigmatic language is used. Instead, we believe that giving diagnosis and support in a holistic and family-centred way is imperative. In delivering a fragile X syndrome diagnosis, the strengths of those living with fragile X syndrome should be the starting point, encouraging development that builds on those strengths while supporting the areas of need. This article will set out these more positive aspects of fragile X syndrome to assist those providing a diagnosis of fragile X syndrome. Lay The purpose of this article is to provide a positive framework for a doctor, geneticist, genetic counsellor or other professional to deliver a fragile X syndrome (FXS) diagnosis and offer support. Our aim is to give a more accurate and holistic definition of FXS. This would cover all the aspects of the condition, including its variability and positive aspects. FXS is commonly described in terms of the ‘problems’ associated with it and stigmatic language is used. Instead, we believe that giving diagnosis and support in a holistic and family-centred way is important. In delivering a FXS diagnosis, the strengths of those living with FXS should be the starting point. These strengths should be built on at the same time as supporting areas of need.

1 April 2026
Verified
Report
Closed access
MBMatt Bolz-Johnson
Matt Bolz-Johnson
Kirsten JohnsonKirsten Johnson
Kirsten Johnson
ARAndré Bernard Rietman
André Bernard Rietman
GBGareth Baynam
Gareth Baynam
DHDiana Kwast Hoekstra
Diana Kwast Hoekstra
TKTom Kenny
Tom Kenny
In this literature review conducted by EURORDIS, we examine the psychological and psychosocial needs of people living with a rare condition and their families. The findings highlight that people living with a rare condition and their families face common and persistent challenges. These include chronic uncertainty, limited access to reliable information, stigma, social isolation, and difficulties navigating fragmented healthcare systems. Many individuals and caregivers also take on the role of coordinating care themselves, often without adequate support. The report emphasises that psychological needs evolve over time, particularly at key stages such as diagnosis, disease progression, and transition to adult care. Despite this, psychological and psychosocial support remains a major unmet need across the rare disease community. In response, the report calls for more integrated, family-centred and multidisciplinary care, with psychological support embedded throughout the care pathway and stronger links with patient organisations to better support individuals and families.

1 April 2026
Verified
Report
Closed access
MBMatt Bolz-Johnson
Matt Bolz-Johnson
Kirsten JohnsonKirsten Johnson
Kirsten Johnson
ARAndré Bernard Rietman
André Bernard Rietman
GBGareth Baynam
Gareth Baynam
DHDiana Kwast Hoekstra
Diana Kwast Hoekstra
TKTom Kenny
Tom Kenny
In this EURORDIS paper, we explore the importance of psychological support to live will with a rare disease. The literature review highlights the importance of integrating psychological and psychosocial support into rare disease care pathways, particularly at key stages such as diagnosis and disease progression, when emotional distress and uncertainty are often highest. The findings demonstrate that family-centred and community-based approaches improve wellbeing. Interventions that strengthen coping strategies, such as acceptance, resilience, and self-efficacy, are associated with better mental health outcomes and quality of life. Access to peer support, social networks, and clear, reliable information also plays a key role in helping individuals and families manage the challenges of living with a rare condition. The paper calls for more holistic, multidisciplinary and psychologically informed care models, with psychological support embedded throughout care pathways. It also calls for stronger policy action to address gaps in provision and ensure equitable access to mental health and psychosocial support across rare disease systems.